|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1999-10-20
|
|
pubmed:abstractText |
Patients with chronic hepatitis C virus (HCV) infection have an increased risk of developing cirrhosis or hepatocellular carcinoma. Consensus interferon (CIFN) offers sustained clinical efficacy to patients studied in the Western countries. This randomized, double-blind, controlled trial in 75 Chinese patients with chronic hepatitis C compared treatment with CIFN or placebo to determine whether CIFN had efficacy and safety in Chinese patients similar to that in Western patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0002-9270
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2496-500
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10484014-Antiviral Agents,
pubmed-meshheading:10484014-China,
pubmed-meshheading:10484014-Double-Blind Method,
pubmed-meshheading:10484014-Female,
pubmed-meshheading:10484014-Hepatitis C, Chronic,
pubmed-meshheading:10484014-Humans,
pubmed-meshheading:10484014-Interferon Type I,
pubmed-meshheading:10484014-Interferon-alpha,
pubmed-meshheading:10484014-Male,
pubmed-meshheading:10484014-Middle Aged,
pubmed-meshheading:10484014-Recombinant Proteins
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C.
|
|
pubmed:affiliation |
Department of Medicine, Veterans General Hospital-Taipei and National Yang-Ming University School of Medicine, Taiwan, Republic of China.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
